Janssen/Pharmacyclics drug Imbruvica 2nd FDA 'breakthrough' to cross finish line

The FDA’s earlier-than-expected approval of Janssen's and Pharmacyclics' Imbruvica (ibrutinib) may be a sign the breakthrough therapy designation is doing its job of expediting the pathway for medicines from development to the marketplace.